ArticleBMC cancer2020
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.Radiology. Imaging cancer · 2022Trial
- Imaging-derived biomarkers fromCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Role ofFrontiers in medicine · 2025Article
- Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM).Journal of endocrinological investigation · 2025Review
- Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers.Journal of clinical medicine · 2024Review
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
- The use of PET/MRI in radiotherapy.Insights into imaging · 2024Review
- Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT.European journal of nuclear medicine and molecular imaging · 2024Article
- Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.Diagnostics (Basel, Switzerland) · 2024Review
- Prediction ofCancers · 2023Article
- Gastroenteropancreatic Neuroendocrine Tumors-Current Status and Advances in Diagnostic Imaging.Diagnostics (Basel, Switzerland) · 2023Review
- Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs).Life (Basel, Switzerland) · 2023Review
- Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.Cancers · 2023Review
- DOTATOC PET/CT imaging of a typical carcinoid tumor in a human ex-vivo perfused lung lobe.Quantitative imaging in medicine and surgery · 2023Article
- Review
- Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update.Journal of clinical medicine · 2022Review
- Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters.Biomedicines · 2022Article
- Article
- Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.Cancers · 2022Review
- [Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTRs), which is the molecular basis for
methodsPatients with histopathologically confirmed NET, at least one liver metastasis > 1 cm and at least two
results29 pairs of
conclusionsPatients responding to current treatment showed a statistically significant decrease in lesion volume on ADC maps and a borderline significant decrease in entropy. No statistically significant changes in PET parameters were observed. No PET or ADC maps parameters predicted treatment response to PRRT. However, the sample size of this preliminary study is small and further research needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.